# Quantum Biochemistry Insights into Ligand Recognition at the a1A-Adrenoceptor

## TL;DR

This study uses quantum biochemistry to explore how different ligands interact with the α1A-adrenoceptor, revealing key molecular interactions that could help design better drugs.

## Contribution

The study introduces a quantum biochemistry approach combining DFT and MFCC to model ligand-receptor interactions at atomic resolution.

## Key findings

- The MFCC-DFT protocol accurately reproduced experimental ligand affinity rankings for α1A-AR.
- Key residues ASP106, VAL107, PHE288, and PHE312 are crucial for ligand binding across all tested compounds.
- Tamsulosin interacts with extracellular residues, contributing to its high selectivity and antagonistic behavior.

## Abstract

Understanding the molecular basis of ligand recognition
at α1A-adrenoceptor (α1A-AR) is
essential for
developing highly selective therapeutic agents. In this study, we
applied a quantum biochemistry approach combining density functional
theory (DFT) with the molecular fractionation with conjugate caps
(MFCC) method to perform a detailed energetic characterization of
the interactions between α1A-AR and three ligands
with distinct pharmacological profiles: the endogenous nonselective
agonist noradrenaline, the partial and selective α1A-AR agonist oxymetazoline, and the selective α1A-AR antagonist tamsulosin. Our calculations of total binding energy
accurately reproduced the experimental relative affinity ranking (tamsulosin
> oxymetazoline > noradrenaline), supporting the reliability
of the
MFCC-DFT protocol in modeling receptor–ligand interactions
at quantum resolution. A total of 81, 88, and 93 amino acid residues
of α1A-AR interacted with noradrenaline, oxymetazoline,
and tamsulosin, respectively. The most energetically relevant residues
were located within 4 Å. A comprehensive residue-level analysis
revealed that ASP106, VAL107, PHE288, and PHE312 are key contributors
to the total binding energy of all ligands, corroborating evidence
from structural and mutagenesis studies. Specifically for oxymetazoline,
this ligand contains a tert-butyl group that establishes
nonpolar interactions with residues such as VAL185 and ALA189, which
are not observed in the noradrenaline-α1A-AR complex.
Additionally, unlike noradrenaline, oxymetazoline exhibits an attractive
interaction with MET292 and does not engage in polar interactions
with SER188. These differential interaction patterns may contribute
to the distinct pharmacological profile of oxymetazoline relative
to noradrenaline. Tamsulosin also exhibited a distinct interaction
profile compared to agonists noradrenaline and oxymetazoline, interacting
with residues located in the extracellular vestibule, including SER83,
PHE86, GLU87, TRP102, CYS176, and LYS309. These additional interactions
play a pivotal role in stabilizing tamsulosin within the binding pocket,
contributing to its high selectivity and antagonistic behavior at
the α1A-AR. Altogether, these findings provide a
robust theoretical framework for understanding the molecular determinants
of functional selectivity and subtype specificity at α1A-AR, offering valuable insights for the rational design of new ligands
with improved selectivity, efficacy, and safety profiles.